Risk Management

Anti-VEGF Drugs for Adults

Vascular endothelial growth factor, or VEGF, is a protein that stimulates the growth of new blood vessels. Ophthalmologists administer intravitreal anti-VEFG agents to adults for a variety of indications. These include Avastin, BEOVU, Lucentis, and Eylea. Sometimes the indication has been approved by the Food and Drug Administration (FDA), other times it is off-label, or the medication itself may never have been approved for any eye indication.

Time out before intravitreal injections is a sample protocol to verify the patient, drug, dose, etc.

AntiVEGF for adults (updated 2023) presents suggestions to increase patient safety and decrease the likelihood of lawsuits related to these drugs. It also provides information about our revised sample consent documents for anti-VEGF agents:

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.